<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Bipolar mania and hypomania in adults: Choosing pharmacotherapy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Bipolar mania and hypomania in adults: Choosing pharmacotherapy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Bipolar mania and hypomania in adults: Choosing pharmacotherapy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey Stovall, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Keck, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Solomon, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 29, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bipolar disorder is marked by episodes of mania  (
         <a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">
          table 1
         </a>
         ) and hypomania  (
         <a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">
          table 2
         </a>
         ), and nearly always includes episodes of major depression  (
         <a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. Despite clinical differences between manic and hypomanic episodes, they are treated with the same medications [
         <a href="#rid2">
          2-9
         </a>
         ].
        </p>
        <p>
         This topic reviews choosing pharmacotherapy for acute mania and hypomania in adults. The general principles of administering pharmacotherapy for acute mania and hypomania in adults are discussed separately, as are pharmacotherapy for acute bipolar depression and maintenance treatment. (See
         <a class="medical medical_review" href="/z/d/html/119372.html" rel="external">
          "Acute bipolar mania and hypomania in adults: General principles of pharmacotherapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15267.html" rel="external">
          "Bipolar major depression in adults: Choosing treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/680.html" rel="external">
          "Bipolar disorder in adults: Choosing maintenance treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H259896878">
         <span class="h1">
          DEFINITION OF BIPOLAR DISORDER
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bipolar disorder is characterized by episodes of mania  (
         <a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">
          table 1
         </a>
         ), hypomania  (
         <a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">
          table 2
         </a>
         ), and major depression  (
         <a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic episodes and nearly always experience hypomanic and major depressive episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic episodes. Episodes of mania, hypomania, and major depression can be accompanied by symptoms of the opposite polarity and are referred to as mood episodes with mixed features (eg, mania with mixed features). Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14642.html" rel="external">
          "Bipolar disorder in adults: Clinical features"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">
          "Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         Despite clinical differences among manic and hypomanic episodes (eg, hypomania is less severe than mania), they are treated with the same medications [
         <a href="#rid2">
          2-9
         </a>
         ].
        </p>
        <p>
         Pharmacotherapy for manic episodes depends upon their severity. Although there are no established criteria that demarcate severe episodes from mild to moderate illness, we classify episodes as severe if they include any of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suicidal ideation or behavior
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Homicidal ideation or behavior
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aggressive behavior
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psychotic features (ie, delusions or hallucinations)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poor judgment that places the patient or others at imminent risk of being harmed
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H324798">
         <span class="h1">
          GENERAL TREATMENT PRINCIPLES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The general principles and issues that are involved in treating acute bipolar mania and hypomania include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nature of the evidence
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Similar approach for mania and hypomania
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment and monitoring
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Level of care
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Goals
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug classes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Duration of an adequate trial
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Predictors of response
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Relapse during maintenance treatment
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Destabilizing drugs
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Indications for referral
        </p>
        <p>
        </p>
        <p>
         These general principles are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/119372.html" rel="external">
          "Acute bipolar mania and hypomania in adults: General principles of pharmacotherapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7954915">
         <span class="h1">
          SEVERE MANIC EPISODES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Severe episodes of mania or mania with mixed features are medical emergencies that are characterized by suicidal or homicidal ideation or behavior, aggressiveness, psychotic features (eg, delusions or hallucinations), and/or poor judgment that places the patient or others at imminent risk of being harmed [
         <a href="#rid9">
          9,10
         </a>
         ]. Severely ill patients generally require hospitalization.
        </p>
        <p class="headingAnchor" id="H2395070399">
         <span class="h2">
          Approach to treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest that acute treatment of severe mania proceed according to the sequence depicted in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef119471" href="/z/d/graphic/119471.html" rel="external">
          algorithm 1
         </a>
         ) and described in the sections below. Patients begin with initial treatment and progress through each step until they respond. The duration of an adequate treatment trial is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/119372.html" rel="external">
          "Acute bipolar mania and hypomania in adults: General principles of pharmacotherapy", section on 'Duration of an adequate trial'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2269895045">
         <span class="h2">
          Initial treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with severe mania, we suggest initial treatment with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         plus an antipsychotic; however,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         plus an antipsychotic is a reasonable alternative  (
         <a class="graphic graphic_algorithm graphicRef119471" href="/z/d/graphic/119471.html" rel="external">
          algorithm 1
         </a>
         ). We generally combine lithium or valproate with
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         . Other antipsychotics that are used less frequently include
         <a class="drug drug_general" data-topicid="8630" href="/z/d/drug information/8630.html" rel="external">
          asenapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">
          cariprazine
         </a>
         , or
         <a class="drug drug_general" data-topicid="10174" href="/z/d/drug information/10174.html" rel="external">
          paliperidone
         </a>
         , as well as a first-generation antipsychotic other than haloperidol. Prescribing medication combinations for severe mania is consistent with multiple treatment guidelines [
         <a href="#rid2">
          2,6-9,11,12
         </a>
         ].
        </p>
        <p>
         No head-to-head trials have compared
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         plus an antipsychotic with
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         plus an antipsychotic. Thus, the choice between lithium and valproate, and the choice of a specific antipsychotic is based upon other factors, including the patient’s past response to medications, the past response of family members with bipolar disorder to medications, specific manic symptoms, side effect profiles, comorbid general medical illnesses, potential for drug-drug interactions, availability of specific drug preparations (eg, intramuscular or oral disintegrating), patient preference, and cost [
         <a href="#rid6">
          6-8
         </a>
         ]. As an example, patients with:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Renal disease generally avoid
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liver disease generally avoid
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sensitivity to extrapyramidal symptoms generally avoid
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obesity generally avoid
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
        </p>
        <p>
        </p>
        <p>
         In addition, women of childbearing age generally avoid
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         .
        </p>
        <p>
         Medication side effects are discussed in more detail separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="local">
          'Medication doses and side effects'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15317.html" rel="external">
          "Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects", section on 'Managing lithium adverse effects'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14773.html" rel="external">
          "First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Based upon several meta-analyses of randomized trials in patients with severe mania, the combination of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         or
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         plus an antipsychotic is more efficacious than monotherapy [
         <a href="#rid13">
          13-15
         </a>
         ]. As an example, a systematic review identified 19 trials that compared combination therapy with monotherapy in a total of 4250 patients with pure mania or mania with mixed features; most of the trials included patients with psychotic features who were hospitalized [
         <a href="#rid16">
          16
         </a>
         ]. Combination therapy primarily consisted of lithium or valproate plus an antipsychotic; three studies included patients who received
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         plus an antipsychotic. The antipsychotics consisted of
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="8630" href="/z/d/drug information/8630.html" rel="external">
          asenapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10174" href="/z/d/drug information/10174.html" rel="external">
          paliperidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         , and
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         . In the meta-analyses that were conducted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improvement of mania was greater with combination therapy than monotherapy with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         , or
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         . However, the clinical advantage of combination therapy over monotherapy was small and heterogeneity across studies was moderate. Although discontinuation of treatment due to adverse effects was comparable for the two groups, somnolence occurred in more than twice as many patients who received combination therapy than monotherapy, and weight gain was increased by nearly a factor of four with combination therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improvement of mania was greater with combination therapy than monotherapy with antipsychotics, the clinical benefit was small to moderate, there was no heterogeneity across studies, and discontinuation of treatment due to adverse effects was comparable for the two groups.
        </p>
        <p>
        </p>
        <p>
         We generally avoid combining
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         with an antipsychotic, based upon randomized trials that found this combination is no more efficacious than carbamazepine alone [
         <a href="#rid17">
          17,18
         </a>
         ]. Carbamazepine induces hepatic enzymes that metabolize antipsychotics, and in one trial lowered the antipsychotic blood level by 40 percent [
         <a href="#rid18">
          18
         </a>
         ]. Specific medication interactions that can occur may be determined using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included in UpToDate.
        </p>
        <p>
         In addition, two randomized trials indicate that adding
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         or divalproex is not efficacious [
         <a href="#rid13">
          13,19
         </a>
         ]. As an example, a three-week trial assigned 656 patients with pure mania or mania with mixed features who had not responded to either lithium or divalproex to receive adjunctive treatment twice per day with ziprasidone 20 to 40 mg, ziprasidone 60 to 80 mg, or placebo [
         <a href="#rid19">
          19
         </a>
         ]. Neither high-dose nor low-dose ziprasidone provided any benefit.
        </p>
        <p>
         When prescribing a medication combination, both drugs are started and titrated up simultaneously. The doses and side effects of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         , and antipsychotics are discussed elsewhere in this topic. (See
         <a class="local">
          'Medication doses and side effects'
         </a>
         below.)
        </p>
        <p>
         Patients who cannot tolerate combination pharmacotherapy are treated with monotherapy. (See
         <a class="local">
          'First-line monotherapy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H7956384">
         <span class="h2">
          Treatment-resistant patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         A severe manic episode that does not respond to one medication combination should be treated with a second medication combination  (
         <a class="graphic graphic_algorithm graphicRef119471" href="/z/d/graphic/119471.html" rel="external">
          algorithm 1
         </a>
         ). Generally,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         is switched to
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         or vice versa. As an example, for patients who do not respond to initial treatment with lithium plus
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         within two weeks of reaching target doses, we suggest tapering and discontinuing lithium at the same time that valproate is started and titrated up. Lithium is generally tapered over one week by the same amount for each dose decrease (eg, lithium 1800 mg per day is decreased by 600 mg per day, every one to two days). The dose and side effects of lithium and valproate are discussed separately. (See
         <a class="local">
          'Lithium'
         </a>
         below and
         <a class="local">
          'Anticonvulsants'
         </a>
         below.)
        </p>
        <p>
         Conversely, for patients who do not respond to initial treatment with
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         plus
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         within two weeks of reaching target doses, we suggest tapering and discontinuing valproate at the same time that
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         is started and titrated up. Valproate is generally tapered over one week by the same amount for each dose decrease (eg, valproate 2000 mg per day is decreased by 500 mg per day, every one to two days).
        </p>
        <p>
         For patients who do not respond to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         plus an antipsychotic, as well as
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         plus the same antipsychotic, we suggest starting a third medication combination involving lithium or valproate plus an antipsychotic. The choice between lithium and valproate is based upon efficacy and tolerability in the two prior trials. In addition, the antipsychotic used in the two prior trials is discontinued and a new one chosen from among
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         (or another first-generation antipsychotic),
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         .
        </p>
        <p>
         The antipsychotic is generally tapered over one week by the same amount for each dose decrease (eg,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         10 mg per day is decreased by 5 mg per day, every one to two days), and at the same time, the other antipsychotic is started and titrated up. The dose and side effects of antipsychotics are discussed separately. (See
         <a class="local">
          'Antipsychotics'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H7956632">
         <span class="h2">
          Treatment-refractory patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest electroconvulsive therapy (ECT) for refractory patients whose manic episode does not respond to four to six medication combinations [
         <a href="#rid2">
          2,20,21
         </a>
         ]. Using ECT for mania that does not respond to pharmacotherapy is consistent with practice guidelines [
         <a href="#rid6">
          6-9,12
         </a>
         ].
        </p>
        <p>
         ECT is generally safe and there are no absolute contraindications, even in patients whose general medical status is compromised [
         <a href="#rid22">
          22
         </a>
         ]. Nevertheless, safety concerns regarding ECT necessitate preprocedure medical consultation. Potential adverse effects include cardiopulmonary events, aspiration pneumonia, fractures, dental and tongue injuries, headache, nausea, and cognitive impairment. Adverse effects of ECT and medical consultation prior to ECT are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1709.html" rel="external">
          "Overview of electroconvulsive therapy (ECT) for adults", section on 'Adverse effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4817.html" rel="external">
          "Medical evaluation for electroconvulsive therapy"
         </a>
         .)
        </p>
        <p>
         Electrode placement and other aspects of ECT technique for treating mania have not been standardized. Thus, ECT is typically administered with the same technique used for other indications and is generally given three times per week on alternating days. Most patients, regardless of indication, remit with 6 to 12 treatments, but some patients may require 20 or more. Additional information about ECT is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1709.html" rel="external">
          "Overview of electroconvulsive therapy (ECT) for adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1712.html" rel="external">
          "Technique for performing electroconvulsive therapy (ECT) in adults"
         </a>
         .)
        </p>
        <p>
         Several studies suggest that ECT is effective for mania. (See
         <a class="medical medical_review" href="/z/d/html/14659.html" rel="external">
          "Bipolar disorder in adults: Indications for and efficacy of electroconvulsive therapy", section on 'Mania'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H326320">
         <span class="h2">
          Other options
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clozapine
         </strong>
         – For patients with refractory mania who decline ECT, do not remit with it, or have no access to it, and who do not respond to medication combinations involving
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         or
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         plus
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         (or another first-generation antipsychotic),
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         , or
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         , we suggest pharmacotherapy with
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         , either as monotherapy or combined with lithium or valproate. Using clozapine for mania that does not respond to other medications is consistent with multiple practice guidelines [
         <a href="#rid6">
          6,7,9,12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The standard schedule for administering
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         is to start treatment at a dose of 12.5 or 25 mg at bedtime, and then increase the dose by 25 mg per day every two days as tolerated, to a target dose of 150 to 450 mg two times per day. Although one retrospective study in patients with refractory manic or mixed episodes (n = 67) concluded that more rapid titration was safe and associated with shorter hospital stays, we generally use the standard schedule for prescribing clozapine as part of routine clinical care.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          Clozapine
         </a>
         can cause agranulocytosis and other blood dyscrasias, and clinicians must monitor complete blood counts every one or two weeks. Clozapine is also associated with the metabolic syndrome. Thus, patients taking clozapine should be regularly monitored for weight, waist circumference, blood pressure, and serum glucose and lipids. Additional information about administering clozapine and its side effects is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14772.html" rel="external">
          "Schizophrenia in adults: Guidelines for prescribing clozapine"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Low-quality evidence suggests that
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         may ameliorate refractory mania. One review identified 10 prospective observational studies, 3 retrospective studies, and 2 randomized trials; the total sample included more than 1000 patients who were manic, depressed, rapid cycling, and/or psychotic [
         <a href="#rid23">
          23
         </a>
         ]. Clozapine was used as add-on therapy or as monotherapy. Across the studies, the results suggested that clozapine was beneficial and relatively well tolerated. Serious adverse effects included leukopenia (1.7 percent of patients), agranulocytosis (0.3 percent), and seizures (0.5 percent). The most common side effects were sedation (12 percent), sialorrhea (5 percent), constipation (5 percent), and weight gain (4 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatments with potential benefit
         </strong>
         – Patients unresponsive to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         or
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         plus
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         may possibly benefit from
         <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">
          allopurinol
         </a>
         plus lithium,
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         monotherapy or tamoxifen plus lithium, and wearing glasses that block blue wavelength light. No head-to-head trials have compared these other treatment options. Thus, the choice is based upon other factors, including past response to medications, side effect profiles, comorbid general medical conditions, potential for drug-drug interactions, patient preference, and cost.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Allopurinol
         </strong>
         –
         <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">
          Allopurinol
         </a>
         , which is typically used to prevent attacks of gouty arthritis and nephropathy, appears to be beneficial as add-on treatment for acute mania, based upon meta-analyses of small randomized trials [
         <a href="#rid24">
          24,25
         </a>
         ]. As an example, a meta-analysis of five inpatient and outpatient trials lasting four to eight weeks compared adjunctive allopurinol (300 or 600 mg/day) with placebo in patients with pure mania or mania with mixed features (n = 433); the patients had not responded to initial treatment with antipsychotics,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , and/or
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         [
         <a href="#rid26">
          26
         </a>
         ]. Improvement was greater with add-on allopurinol and the clinical benefit was small to moderate; in addition, adverse effects were comparable with active drug and placebo.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tamoxifen
         </strong>
         –
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          Tamoxifen
         </a>
         is a centrally active protein kinase C inhibitor that may be beneficial for refractory mania, either as monotherapy or combined with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         or
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         . However, the drug is widely used to prevent breast cancer because it is a selective estrogen receptor antagonist, and these antiestrogen effects preclude its use beyond patients with severe mania who are unresponsive to most or all other treatments. This approach is consistent with multiple practice guidelines [
         <a href="#rid6">
          6,8,9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Evidence supporting the use of
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         for mania includes several small randomized trials [
         <a href="#rid27">
          27-29
         </a>
         ]. The largest trial compared tamoxifen (20 to 40 mg two times per day) with placebo for three weeks in 66 patients hospitalized with pure mania or mania with mixed features [
         <a href="#rid30">
          30
         </a>
         ]. Response (reduction of baseline symptoms ≥50 percent) occurred in more patients who received tamoxifen than placebo (48 versus 5 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Blue-blocking glasses
         </strong>
         – Wearing orange tinted glasses that block the blue light spectrum, which may be akin to dark therapy, may help improve manic symptoms. A small, open-label, one-week randomized trial compared add-on blue-blocking glasses with clear lens glasses in patients hospitalized with acute mania (n = 23) [
         <a href="#rid31">
          31
         </a>
         ]. The glasses were worn each day from 6 p.m. to 8 AM, and patients received pharmacotherapy that included antipsychotics,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , and
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         . Improvement was greater with blue-blocking glasses than clear lens glasses, and the clinical effect was large despite the use of less intense pharmacotherapy for the group wearing blue-blocking glasses. Adverse effects of the blue-blocking glasses included emerging depressive symptoms in two patients, which remitted by decreasing use of the glasses.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2213838842">
         <span class="h2">
          Treatments with little to no benefit
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is little or no evidence to support treating acute mania with anticonvulsants other than
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         and
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         . Based upon randomized trials,
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         , and
         <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">
          zonisamide
         </a>
         are not effective for treating mania [
         <a href="#rid6">
          6,32-36
         </a>
         ]. In addition, a systematic review found that there were no randomized trials involving
         <a class="drug drug_general" data-topicid="10144" href="/z/d/drug information/10144.html" rel="external">
          tiagabine
         </a>
         , and results from observational studies were conflicting [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         Nor do we suggest using
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         , which has been substituted for
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         to treat mania because their molecular structures are similar and oxcarbazepine has fewer side effects. There is no high quality evidence that oxcarbazepine has any benefit in adults [
         <a href="#rid34">
          34,38
         </a>
         ]. In addition, a randomized trial found that oxcarbazepine and placebo were comparable in 116 children and adolescents with pure mania or mania with mixed features [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         The calcium channel blocker
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         has also not demonstrated efficacy for mania [
         <a href="#rid34">
          34
         </a>
         ]. A meta-analysis of two randomized trials compared verapamil (480 mg/day in divided doses) with placebo in patients with acute mania (total n = 46) and found that improvement was comparable for the two groups [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9945243">
         <span class="h2">
          Agitation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Agitation is defined as nonproductive, excess motor activity in conjunction with inner tension [
         <a href="#rid1">
          1,41
         </a>
         ], and is common in severe mania, especially mania with mixed features [
         <a href="#rid6">
          6
         </a>
         ]. The initial assessment of agitation in patients with a known diagnosis of bipolar disorder should focus upon determining whether the agitation is due to causes beyond mania, such as a general medical disorder, or intoxication or withdrawal from alcohol or other substances such as cocaine or methamphetamines [
         <a href="#rid42">
          42
         </a>
         ]. In addition, clinicians should assess safety, including risk for suicide, and develop a treatment plan.
        </p>
        <p>
         Hospitalized patients with mania who are acutely agitated often require oral, inhaled, or intramuscular medications to manage threatening or aggressive behavior, and may also require seclusion and physical restraints [
         <a href="#rid6">
          6,7,9
         </a>
         ]. Oral or inhaled formulations are used for mild to moderate agitation, and intramuscular formulations for severe agitation. Patients with severe mania generally receive antipsychotics (eg,
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         , or
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ) as part of their daily medication regimen (see
         <a class="local">
          'Initial treatment'
         </a>
         above), and the same antipsychotic is typically used on an as needed basis for controlling acute behavioral disturbances.
        </p>
        <p>
         Multiple studies support treating severe manic agitation with a short-acting, intramuscular injection of a first- or second-generation antipsychotic. As an example, a randomized trial found that among psychiatric inpatients with various diagnoses who received
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         for acute agitation (n = 110), the median time to sedation was 20 minutes, and sedation within 120 minutes occurred in 92 percent [
         <a href="#rid43">
          43
         </a>
         ]. Other studies have found that intramuscular
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         , and
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         can also be efficacious [
         <a href="#rid6">
          6,44,45
         </a>
         ]. In addition, patients not responding to initial monotherapy can be treated with the combination of an antipsychotic and benzodiazepine, such as haloperidol plus
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         or
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         Agitation can also be managed with benzodiazepine monotherapy [
         <a href="#rid6">
          6,7,9
         </a>
         ]. As an example, agitation may be secondary to akathisia that is caused by an antipsychotic, particularly a first-generation drug such as
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ; in these cases, agitation can be treated with a benzodiazepine such as
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         , using a dose of 0.5 to 2 mg.
        </p>
        <p>
         For mild to moderate agitation in patients who cannot tolerate as needed antipsychotics or benzodiazepines, another option is
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         . Evidence supporting its use includes a randomized trial that enrolled 378 patients with bipolar disorder and mild to moderate agitation; nearly 80 percent were treated with daily medications for bipolar disorder. Patients were randomly assigned to receive a single dose of dexmedetomidine 180 mcg, dexmedetomidine 120 mcg, or placebo, which was self-administered as a sublingual dissolving film [
         <a href="#rid46">
          46
         </a>
         ]. Improvement of agitation was greater with dexmedetomidine 180 mcg or 120 mcg than placebo, beginning 20 minutes after taking the study drug and continuing for two hours. The efficacy of the two dexmedetomidine doses was comparable. However, the incidence of adverse events was two times greater with dexmedetomidine 180 mcg or 120 mcg than placebo (36, 35, and 17 percent of patients). The most common side effects with active drug included somnolence, dry mouth, hypotension, and dizziness. Although dexmedetomidine did not prolong the QT interval in this trial, other studies indicate that the drug can cause generally mild prolongation of the QT interval [
         <a href="#rid47">
          47
         </a>
         ]. Thus, the drug should be avoided in patients at increased risk for QT prolongation, including patients taking other drugs that can prolong the QT interval  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes"
         </a>
         .)
        </p>
        <p>
         Information about managing acute agitation in the emergency department is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/291.html" rel="external">
          "Assessment and emergency management of the acutely agitated or violent adult", section on 'Management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3368387423">
         <span class="h2">
          Decreased need for sleep
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with mania often present with a decreased need for sleep, and may feel rested after a few hours of sleep or may not sleep at all for several consecutive days; decreased need for sleep differs from insomnia, in which the individual wants to sleep but cannot [
         <a href="#rid1">
          1
         </a>
         ]. We frequently include a benzodiazepine such as
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         or
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         in the medication regimen during the first week to promote sleep. (See
         <a class="local">
          'Benzodiazepines'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H186702750">
         <span class="h1">
          HYPOMANIA AND MILD TO MODERATE MANIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypomania and mild to moderate mania are marked by the absence of suicidal or homicidal ideation or behavior, aggressiveness, psychotic features (ie, delusions or hallucinations), and poor judgment that places the patient or others at imminent risk of being harmed. Monotherapy is commonly used for initially treating hypomania and mild to moderate mania.
        </p>
        <p class="headingAnchor" id="H3919655573">
         <span class="h2">
          Approach to treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest that acute treatment of hypomania and mild to moderate mania proceed according to the sequence described in the sections below. Patients begin with initial treatment and progress through each step until they respond. The duration of an adequate treatment trial is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/119372.html" rel="external">
          "Acute bipolar mania and hypomania in adults: General principles of pharmacotherapy", section on 'Duration of an adequate trial'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H991964">
         <span class="h2">
          First-line monotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite clinical differences between manic and hypomanic episodes (eg, hypomania is less severe than mania), they are treated with the same medications [
         <a href="#rid2">
          2-9
         </a>
         ].
        </p>
        <p>
         For patients with either hypomanic or mild to moderate manic episodes, we suggest monotherapy with
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         or
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         , based upon efficacy and tolerability [
         <a href="#rid33">
          33,34
         </a>
         ]. However, reasonable alternatives include
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="8630" href="/z/d/drug information/8630.html" rel="external">
          asenapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">
          cariprazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ,
         <a class="drug drug_general" data-topicid="10174" href="/z/d/drug information/10174.html" rel="external">
          paliperidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         , or
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         . The use of risperidone, olanzapine, or the other drugs is consistent with multiple treatment guidelines [
         <a href="#rid5">
          5-8,12,48
         </a>
         ]. Doses and side effects are discussed elsewhere in the topic. (See
         <a class="local">
          'Medication doses and side effects'
         </a>
         below.)
        </p>
        <p>
         A network meta-analysis of 57 randomized trials (n &gt;14,000 patients with an acute episode of pure mania or mania with mixed features, treated for three or four weeks) found that 12 standard drugs were each more efficacious than placebo:
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="8630" href="/z/d/drug information/8630.html" rel="external">
          asenapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">
          cariprazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10174" href="/z/d/drug information/10174.html" rel="external">
          paliperidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         , and
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         [
         <a href="#rid34">
          34
         </a>
         ]. The nonstandard medication
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         was also more effective than placebo. Five drugs were no more effective than placebo:
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         , licarbazepine,
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         , and
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         .
        </p>
        <p>
         In addition, the network meta-analysis ranked the 12 drugs by efficacy, using indirect comparisons of the drugs (through their relative effect with a common comparator, typically placebo), as well as analyzing direct comparisons between drugs [
         <a href="#rid34">
          34
         </a>
         ]. Beginning with the most efficacious drug, the rank order for efficacy was:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          Risperidone
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          Haloperidol
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          Olanzapine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">
          Cariprazine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          Carbamazepine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10174" href="/z/d/drug information/10174.html" rel="external">
          Paliperidone
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          Aripiprazole
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8630" href="/z/d/drug information/8630.html" rel="external">
          Asenapine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          Quetiapine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          Ziprasidone
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          Valproate
         </a>
         (or divalproex)
        </p>
        <p>
        </p>
        <p>
         Nevertheless, the probability of response (reduction of baseline symptoms ≥50 percent) was comparable across all the drugs.
        </p>
        <p>
         The network meta-analysis also ranked the 12 drugs by frequency of treatment discontinuation for any reason, including adverse effects and lack of efficacy [
         <a href="#rid34">
          34
         </a>
         ]. Beginning with the drug with the lowest rate of dropout, the rank order was:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          Olanzapine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          Risperidone
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10174" href="/z/d/drug information/10174.html" rel="external">
          Paliperidone
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          Quetiapine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          Valproate
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          Aripiprazole
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          Ziprasidone
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          Haloperidol
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8630" href="/z/d/drug information/8630.html" rel="external">
          Asenapine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          Carbamazepine
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">
          Cariprazine
         </a>
        </p>
        <p>
        </p>
        <p>
         The indirect comparisons distinguish this network meta-analysis from smaller, conventional meta-analyses [
         <a href="#rid13">
          13,15,49,50
         </a>
         ]. Although substantial uncertainties are introduced when these sorts of rank orders are created through the indirect comparisons that are used in a network meta-analysis, this may be the best evidence for comparing drugs for acute hypomania and mild to moderate mania. Network meta-analysis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16293.html" rel="external">
          "Systematic review and meta-analysis", section on 'Network meta-analysis'
         </a>
         .)
        </p>
        <p>
         Clinicians should consider other factors in addition to the rank order of efficacy and treatment discontinuation when choosing a drug, including the patient’s past response to medications, the past response of family members with bipolar disorder to medications, specific manic symptoms, adverse drug effects, comorbid general medical illnesses, potential for drug-drug interactions, availability of specific drug preparations (eg, oral disintegrating), patient preference, and cost. As an example, patients with:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Renal disease generally avoid
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liver disease generally avoid
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sensitivity to extrapyramidal symptoms generally avoid
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obesity generally avoid
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
        </p>
        <p>
        </p>
        <p>
         In addition, women of childbearing age generally avoid
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         .
        </p>
        <p>
         Medication side effects are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="local">
          'Medication doses and side effects'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15317.html" rel="external">
          "Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects", section on 'Managing lithium adverse effects'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14773.html" rel="external">
          "First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The long-term implications of choosing a drug also need to be considered; all patients with bipolar disorder should receive maintenance treatment, which commonly consists of the drug used to induce remission. As an example, maintenance
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         is common because it has been widely studied and is efficacious [
         <a href="#rid51">
          51,52
         </a>
         ], and long-term treatment with lithium may reduce the risk of suicide attempts and deaths [
         <a href="#rid53">
          53
         </a>
         ]. By contrast,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         is generally not used in maintenance treatment because it can cause movement disorders and may increase the risk of bipolar major depression [
         <a href="#rid54">
          54,55
         </a>
         ]. Although
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         is efficacious for pure mania as well as mania with mixed features [
         <a href="#rid56">
          56
         </a>
         ], olanzapine is not a first-line drug for maintenance treatment because of concerns about weight gain and diabetes mellitus.
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          Valproate
         </a>
         is often not prescribed to women of childbearing potential because many pregnancies are unplanned and the drug is generally regarded as teratogenic [
         <a href="#rid57">
          57
         </a>
         ]. Maintenance treatment is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/680.html" rel="external">
          "Bipolar disorder in adults: Choosing maintenance treatment"
         </a>
         .)
        </p>
        <p>
         For patients with hypomania or mild to moderate mania, who do not respond to treatment with one monotherapy trial within two weeks of reaching the target dose or do not tolerate the drug, we suggest tapering and discontinuing the failed medication over one week at the same time that another monotherapy is started and titrated up. The failed medication is generally tapered by the same amount for each dose decrease. As an example,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         600 mg per day is decreased by 100 to 200 mg per day, every one to two days.
        </p>
        <p class="headingAnchor" id="H7954899">
         <span class="h2">
          Treatment resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         For hypomanic and mild to moderate manic episodes that do not respond to three to five monotherapy trials involving
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         , and
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         , we suggest combining lithium or valproate with an antipsychotic [
         <a href="#rid6">
          6,9,12
         </a>
         ]. However, lithium plus valproate is a reasonable alternative [
         <a href="#rid9">
          9,12,58,59
         </a>
         ]. Medication combinations involving lithium or valproate plus an antipsychotic are discussed elsewhere in the topic. (See
         <a class="local">
          'Initial treatment'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H226715129">
         <span class="h3">
          Benzodiazepines
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         for patients who have hypomanic or mild to moderate manic or mixed episodes and cannot tolerate
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , anticonvulsants, or antipsychotics [
         <a href="#rid6">
          6
         </a>
         ]. However,
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         is a reasonable alternative.
        </p>
        <p>
         Benzodiazepine monotherapy is unusual due to the large number of available medication options for manic and hypomanic episodes; instead, benzodiazepines are generally used as adjunctive therapy to treat insomnia, agitation, or anxiety in patients with pathologic mood elevated syndromes [
         <a href="#rid7">
          7,9
         </a>
         ]. Given the high rate of substance use disorders among bipolar patients and the potential for abusing benzodiazepines, these drugs are generally limited to acute treatment [
         <a href="#rid60">
          60
         </a>
         ]. However, maintenance treatment with benzodiazepines is administered to catatonic patients who remit with benzodiazepines. (See
         <a class="medical medical_review" href="/z/d/html/15869.html" rel="external">
          "Catatonia: Treatment and prognosis", section on 'Benzodiazepine safety and administration'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          Clonazepam
         </a>
         is usually started at a dose of 1 to 3 mg per day, taken in two divided doses. The drug is generally titrated up to a target dose ranging from 2 to 6 mg per day, depending upon efficacy and tolerability, although doses as high as 24 mg per day have been used [
         <a href="#rid61">
          61
         </a>
         ]. Side effects include disinhibition, sedation, and respiratory depression.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          Lorazepam
         </a>
         is usually started at a dose of 2 to 4 mg per day, taken in three to four divided doses. The drug is generally titrated up to a target dose ranging from 3 to 8 mg per day, depending upon efficacy and tolerability, although doses as high as 24 mg per day have been used [
         <a href="#rid61">
          61
         </a>
         ]. Side effects include disinhibition, sedation, and respiratory depression.
        </p>
        <p>
         Evidence of efficacy includes a meta-analysis of five randomized trials (122 manic patients) that compared
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         monotherapy (2 to 24 mg per day) with
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ,
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         , or placebo, and found that clonazepam was efficacious; however, heterogeneity across studies appeared to be substantial [
         <a href="#rid61">
          61
         </a>
         ]. A meta-analysis of four randomized trials (108 manic patients) that compared lorazepam monotherapy (4 to 24 mg per day) with clonazepam, haloperidol, lithium, or placebo found that lorazepam was not effective [
         <a href="#rid61">
          61
         </a>
         ]. However, one randomized trial directly compared lorazepam (mean daily dose 13 mg) with clonazepam (mean daily dose 14 mg) in 24 manic patients, and found that moderate to marked improvement occurred in more patients who received lorazepam than clonazepam (63 versus 18 percent), as did remission (38 versus 0 percent) [
         <a href="#rid62">
          62
         </a>
         ]. The frequency of side effects did not differ between the clonazepam and lorazepam [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H244584">
         <span class="h1">
          MEDICATION DOSES AND SIDE EFFECTS
         </span>
        </p>
        <p class="headingAnchor" id="H1829248939">
         <span class="h2">
          Lithium
         </span>
         <span class="headingEndMark">
          —
         </span>
         The starting dose of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         is usually 300 mg two or three times daily; smaller doses (eg, 150 mg twice daily) are used in the elderly [
         <a href="#rid60">
          60,63-65
         </a>
         ]. The dose should be increased by 300 to 600 mg every one to five days based upon response, tolerability, and body mass index. The goal is to reach a therapeutic serum level, which generally occurs with a dose of 900 mg to 1800 mg per day. Dose increases generally occur more frequently at the beginning of treatment, and less often as clinicians approach the target dose. Additional information about the dose of lithium is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/15317.html" rel="external">
          "Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects", section on 'Lithium dose and serum concentrations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16446.html" rel="external">
          "Geriatric bipolar disorder: Treatment of mania and major depression", section on 'First-line medications'
         </a>
         .)
        </p>
        <p>
         The target serum level for acute treatment is between 0.8 and 1.2 mEq/L (0.8 and 1.2 mmol/L); levels should not exceed 1.2 mEq/L (1.2 mmol/L) to reduce the risk of toxicity [
         <a href="#rid64">
          64
         </a>
         ]. Patients who cannot tolerate a level of 0.8 mEq/L (0.8 mmol/L) may respond to a level of 0.6 to 0.7 mEq/L (0.6 to 0.7 mmol/L).
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         levels should be measured five to seven days after each dose increase. Levels are drawn 12 hours after the last dose (12-hour serum trough level) and generally collected in the morning, before the first dose of the day. Additional information about lithium serum levels is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/15317.html" rel="external">
          "Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects", section on 'Lithium dose and serum concentrations'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         can cause many acute and long-term adverse effects. The most common acute side effects are nausea, tremor, polyuria and thirst, weight gain, loose stools, and cognitive impairment [
         <a href="#rid65">
          65-67
         </a>
         ]. Severe or sudden worsening of acute side effects may be a sign of lithium toxicity. Over the long term, lithium can adversely affect the kidneys and thyroid gland. In addition, cardiac rhythm disturbances have been described; these almost always occur in patients with preexisting cardiac disease.
        </p>
        <p>
         Additional information about
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         side effects and how to manage them, as well as contraindications to lithium, lithium toxicity, drug interactions with lithium, the different available preparations of lithium, and laboratory tests for monitoring patients treated with lithium is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15317.html" rel="external">
          "Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects", section on 'Managing lithium adverse effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/320.html" rel="external">
          "Lithium poisoning"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2358.html" rel="external">
          "Renal toxicity of lithium"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7843.html" rel="external">
          "Lithium and the thyroid"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1829256415">
         <span class="h2">
          Anticonvulsants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anticonvulsants that are efficacious for acute mania and hypomania include
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         and
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         .
        </p>
        <p class="headingAnchor" id="H52498640">
         <span class="h3">
          Suicidality
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bipolar disorder is associated with an increased risk of suicide deaths [
         <a href="#rid68">
          68
         </a>
         ], and all patients should be monitored for emergence or worsening of suicidal thoughts and behavior. Although some observational studies suggest that anticonvulsants may increase the risk of suicidal ideation or behavior, these drugs are generally safe to use when patients are regularly monitored.
        </p>
        <p>
         The US Food and Drug Administration warned clinicians that anticonvulsants are associated with an increased risk of suicidal thoughts and behavior, based upon a pooled analysis of 199 controlled trials that included patients with a variety of illnesses (total n &gt;43,000) [
         <a href="#rid69">
          69
         </a>
         ]. In addition, a separate exploratory analysis of a medical and pharmacy claims database that included 297,620 new episodes of treatment with an anticonvulsant suggested that
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         , and
         <a class="drug drug_general" data-topicid="10144" href="/z/d/drug information/10144.html" rel="external">
          tiagabine
         </a>
         may be associated with an increased risk of suicidal acts or violent deaths, compared with
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         [
         <a href="#rid70">
          70
         </a>
         ]. However, an observational study using data from a medical and pharmacy claims database of geriatric patients with a variety of illnesses (n &gt;90,000) suggested that suicidal thoughts and behavior were more likely to occur during the 30 days prior to initial use of an anticonvulsant than any other time period in the year before and after exposure [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         In addition, an analysis of a different national claims database that involved patients diagnosed with bipolar disorder (n &gt;47,000) found [
         <a href="#rid72">
          72
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The frequency of suicide attempts in patients treated with antiseizure medications and patients not receiving antiseizure medications was comparable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients treated with antiseizure medications, the rate of suicide attempts was greater before treatment than after treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients receiving antiseizure medication monotherapy (and no concomitant antidepressant or antipsychotic) had fewer suicide attempts compared to patients receiving no pharmacotherapy.
        </p>
        <p>
        </p>
        <p>
         Other observational studies have also found that antiseizure medications were not associated with an increased risk of suicidal behavior in bipolar patients [
         <a href="#rid73">
          73
         </a>
         ]. As an example, analyses using a national database with over 5,000,000 patients found that among patients with bipolar disorder, treatment with antiseizure medications was not associated with an increased risk of suicide attempts [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H173223623">
         <span class="h3">
          Carbamazepine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          Carbamazepine
         </a>
         is usually started at a dose of 100 mg to 200 mg one or two times per day [
         <a href="#rid75">
          75
         </a>
         ]. The dose should be increased by 200 mg per day every one to four days, to a final dose of about 800 to 1000 mg per day, although the effective dose may range between 200 and 1800 mg per day. Carbamazepine is typically administered twice daily. Therapeutic serum levels have not been established for treating acute manic episodes. However, many clinicians aim for a level of 4 to 12 mcg/mL, which is the target range established for treating epilepsy. Extended-release formulations are better tolerated in patients with bipolar disorder [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         The major systemic side effects of
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         are nausea, vomiting, diarrhea, hyponatremia, rash, pruritus, leukopenia, and fluid retention  (
         <a class="graphic graphic_table graphicRef59755" href="/z/d/graphic/59755.html" rel="external">
          table 5
         </a>
         ). Neurotoxicity includes drowsiness, dizziness, blurred or double vision, lethargy, and headache. Carbamazepine also induces liver enzymes and frequently causes drug-drug interactions that result in lower serum concentrations of concomitant drugs [
         <a href="#rid60">
          60,77,78
         </a>
         ]. This induction of liver enzymes often decreases serum concentrations of carbamazepine. Liver function tests and a complete blood count, serum sodium, and serum carbamazepine level are recommended every 6 to 12 months.
        </p>
        <p>
         In addition, the drug is associated with life-threatening rashes (Stevens-Johnson syndrome and toxic epidermal necrolysis), particularly during the first eight weeks of therapy  (
         <a class="graphic graphic_table graphicRef78896" href="/z/d/graphic/78896.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid79">
          79
         </a>
         ]. This reaction is significantly more common in patients with the HLA-B*1502 allele (estimated incidence of 5 percent), which occurs almost exclusively in Asian persons [
         <a href="#rid80">
          80-82
         </a>
         ]. Screening for this allele is recommended in patients of this ethnic group prior to starting
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">
          "Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis", section on 'HLA polymorphism and pharmacogenetics'
         </a>
         .)
        </p>
        <p>
         The pharmacology of
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         and its adverse effects and available preparations are discussed in greater detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Carbamazepine'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Valproate or divalproex
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          Valproate
         </a>
         is usually started at a dose of 500 or 750 mg per day; we typically use the delayed-release formulation of divalproex and initially administer it in two or three divided doses. The dose is increased by 250 mg to 500 mg every one to three days as tolerated to reach a therapeutic serum level, which generally occurs with 1500 mg to 2500 mg per day [
         <a href="#rid65">
          65,83
         </a>
         ]. Once the daily dose is established, divalproex (either as a delayed-release or 24-hour extended release formulation) is typically given once daily at bedtime to improve adherence. If an immediate release formulation is needed (eg liquid), it can be given in two divided doses per day once the daily dose is established.
        </p>
        <p>
         Oral loading and rapid titration to a full dose within one to two days by prescribing 20 mg/kg/day may result in earlier improvement in symptoms and a reduced need for adjunctive antipsychotics or benzodiazepines [
         <a href="#rid2">
          2,7,84-87
         </a>
         ]. However, loading 20 mg/kg/day may cause intolerable side effects. In addition, for patients who are obese (eg, 120 kg), we rarely prescribe more than 2000 mg on day 1.
        </p>
        <p>
         We suggest drawing
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         serum levels two to five days after each dose increase and prescribing the drug to achieve a target serum level between 50 and 125 mcg/mL. Levels should be drawn 8 to 12 hours after the last dose and generally collected in the morning, before the first dose of the day. When 24-hour extended-release preparations are administered in the morning, trough levels are drawn the following morning before the next daily dose [
         <a href="#rid88">
          88
         </a>
         ]. When 24-hour extended-release preparations are administered at bedtime, levels are drawn 18 to 24 hours later, prior to the next dose. A post hoc analysis of pooled data from three controlled trials (374 acutely manic inpatients) found that efficacy increased as serum concentrations increased [
         <a href="#rid89">
          89
         </a>
         ]. In addition, the efficacy of valproate was significantly greater than placebo for levels ≥71 mcg/mL, and the largest clinical effect for valproate occurred in patients with a mean serum concentration of 88 mcg/mL. After target serum levels have been achieved, levels should be checked at 6 to 12 month intervals, and are particularly useful in patients receiving medications that affect valproate concentrations and to confirm problems with adherence. Some patients may not require regular valproate levels, and one review concluded that clinical observation of efficacy and toxicity can be used to guide some dose adjustments [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
         Common side effects of
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         include weight gain, nausea, vomiting, hair loss, easy bruising, and tremor  (
         <a class="graphic graphic_table graphicRef59755" href="/z/d/graphic/59755.html" rel="external">
          table 5
         </a>
         ). Divalproex is a formulation of valproate that can minimize gastrointestinal distress. In addition, valproate is rarely associated with hepatic failure and thrombocytopenia  (
         <a class="graphic graphic_table graphicRef78896" href="/z/d/graphic/78896.html" rel="external">
          table 6
         </a>
         ); liver function tests and platelets should thus be monitored at 6- to 12-month intervals in all patients taking the drug [
         <a href="#rid60">
          60,77,78
         </a>
         ]. (The US Food and Drug Administration recommends checking liver function tests prior to initiating treatment and at frequent intervals thereafter, especially during the first six months.) In addition, valproate rarely causes pancreatitis; symptoms of abdominal pain and vomiting should prompt an assessment that includes a serum amylase and lipase.
        </p>
        <p>
         Additional information about the pharmacology of
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         and its adverse effects and available preparations are discussed separately, as well as problems using valproate in women of childbearing age. (See
         <a class="medical medical_review" href="/z/d/html/15701.html" rel="external">
          "Bipolar disorder in women: Contraception and preconception assessment and counseling"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Antipsychotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         First- and second-generation antipsychotics are efficacious for treating both psychotic and nonpsychotic manic and hypomanic episodes [
         <a href="#rid6">
          6,13-15,49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2346270038">
         <span class="h3">
          First-generation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among first-generation antipsychotics, we prefer
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         for treating manic episodes because it has been widely studied and generally causes less orthostatic hypotension and sedation than
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         , which is also efficacious [
         <a href="#rid50">
          50,91
         </a>
         ]. Other first-generation antipsychotics such as
         <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">
          fluphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9576" href="/z/d/drug information/9576.html" rel="external">
          loxapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9993" href="/z/d/drug information/9993.html" rel="external">
          thiothixene
         </a>
         , and
         <a class="drug drug_general" data-topicid="10020" href="/z/d/drug information/10020.html" rel="external">
          trifluoperazine
         </a>
         are effective as well [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
         We suggest patients initially receive
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         at a dose of 2 to 15 mg per day, depending upon the severity of symptoms, the patient’s body mass index, and adverse effects that emerge. The drug is taken either once per day or in two divided doses, depending upon tolerability and the patient’s ability to adhere to treatment with divided doses. One useful guide is to initially prescribe 0.2 mg per kg per day [
         <a href="#rid93">
          93
         </a>
         ]. In a meta-analysis of 15 randomized trials (2022 acutely ill patients with pure mania or mania with mixed features), which found that haloperidol was comparable to
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         , and
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         , the dose of haloperidol ranged from 2 to 85 mg per day [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         Conventional antipsychotics are associated with extrapyramidal symptoms, akathisia, and tardive dyskinesia. Extrapyramidal symptoms are usually managed by lowering the dose of the antipsychotic or by adding an anticholinergic drug, either
         <a class="drug drug_general" data-topicid="9106" href="/z/d/drug information/9106.html" rel="external">
          benztropine
         </a>
         1 to 2 mg two to four times daily or
         <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">
          trihexyphenidyl
         </a>
         2 to 5 mg two to four times daily.
        </p>
        <p>
         Although switching from mania to depression has been attributed to first-generation antipsychotics, the evidence is not clear. A meta-analysis of six randomized trials (1774 manic patients) compared
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         with second-generation antipsychotics (
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         , or
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         ), and found that treatment emergent depression was comparable for patients who received haloperidol or second-generation antipsychotics (10 and 7 percent); heterogeneity across studies was moderate [
         <a href="#rid94">
          94
         </a>
         ]. However, a second analysis that excluded one outlier trial (and eliminated the heterogeneity) found that depressive switches occurred in more patients treated with haloperidol (12 versus 7 percent). In assessing patients treated with an antipsychotic, clinicians should distinguish between switching to a depressive syndrome and the side effect of affective blunting or flattening.
        </p>
        <p>
         The pharmacology, administration, and side effects of first-generation antipsychotics are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14773.html" rel="external">
          "First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4909.html" rel="external">
          "Tardive dyskinesia: Etiology, risk factors, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">
          "Neuroleptic malignant syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2346270045">
         <span class="h3">
          Second-generation
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          Aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         , and
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         are each efficacious for treating mania and hypomania [
         <a href="#rid33">
          33
         </a>
         ], and the choice often depends upon differences in adverse side effects  (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 7
         </a>
         ). Metabolic problems such as weight gain, glucose intolerance, diabetes mellitus, and hyperlipidemia are most likely to occur with olanzapine, followed by quetiapine and risperidone. Thus, patients taking olanzapine, quetiapine, and risperidone should be regularly monitored for weight, waist circumference, blood pressure, and serum glucose and lipids  (
         <a class="graphic graphic_table graphicRef74435" href="/z/d/graphic/74435.html" rel="external">
          table 8
         </a>
         ). Extrapyramidal symptoms are more common with aripiprazole, olanzapine, risperidone, or ziprasidone compared with quetiapine. The metabolic syndrome and extrapyramidal symptoms are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1784.html" rel="external">
          "Metabolic syndrome (insulin resistance syndrome or syndrome X)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">
          "Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Extrapyramidal symptoms'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">
          "Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Metabolic dysregulation'
         </a>
         .)
        </p>
        <p>
         The usual starting and target dose for second-generation antipsychotics that were used in randomized monotherapy trials for mania, and side effects that commonly occurred, are described below [
         <a href="#rid10">
          10,95-101
         </a>
         ]. Target doses can generally be achieved within one week of starting the medication. Some drugs are available as oral dissolvable formulations for patients who pretend to swallow their pills (“cheek”) and spit them out later when clinicians are not looking.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aripiprazole
         </strong>
         –
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          Aripiprazole
         </a>
         is started at a dose of 10 to 30 mg once daily, and is generally titrated in increments of 5 to 10 mg/day at intervals ≥1 week. The usual target dose is 15 to 30 mg taken once per day. Common side effects include headache, nausea, vomiting, constipation, insomnia, and akathisia. An oral dissolvable formulation is available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asenapine
         </strong>
         –
         <a class="drug drug_general" data-topicid="8630" href="/z/d/drug information/8630.html" rel="external">
          Asenapine
         </a>
         is started at 5 or 10 mg twice daily on day 1, and thereafter dosed at 5 or 10 mg two times per day. Some patients may respond to a total daily dose of 15 mg per day, split between two doses. Common side effects include sedation, fatigue, dizziness, extrapyramidal symptoms, vomiting, dry mouth, and weight gain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cariprazine
         </strong>
         – The standard dose range for
         <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">
          cariprazine
         </a>
         is 3 to 12 mg/day once daily. On day 1 the dose is 1.5 mg/day, and on day 2 the dose is 3 mg/day. Depending upon response and tolerability, the dose is subsequently increased by increments of 1.5 or 3 mg/day to a maximum of 12 mg/day. Adverse effects of cariprazine that occur in at least 5 percent of patients and at least twice as often as placebo include akathisia, extrapyramidal symptoms, restlessness, and vomiting. Mean weight change during three weeks of treatment with cariprazine or placebo are 0.5 kg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Olanzapine
         </strong>
         –
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          Olanzapine
         </a>
         is started at a dose of 10 to 15 mg once daily or in two divided doses. The usual target dose is 10 to 30 mg per day, taken at bedtime or in two divided doses. Some patients may require and tolerate 40 or 50 mg per day. Common side effects include sedation, constipation, dry mouth, increased appetite, weight gain, and orthostatic hypotension. An oral dissolvable formulation is available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Paliperidone
         </strong>
         – The standard dose range for
         <a class="drug drug_general" data-topicid="10174" href="/z/d/drug information/10174.html" rel="external">
          paliperidone
         </a>
         is 3 to 12 mg/day once daily. Paliperidone is started at either 3 or 6 mg/day on day 1; thereafter, the dose is titrated up by increments of 3 mg/day every one to three days to a maximum of 12 mg/day, depending upon response and tolerability. The most common adverse events are headache, somnolence, dizziness, akathisia, hypertonia, and dyspepsia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Quetiapine
         </strong>
         <strong>
         </strong>
         –
         <strong>
         </strong>
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          Quetiapine
         </a>
         immediate release is started at a dose of 100 to 200 mg once daily or in two divided doses. The usual target dose is 400 to 800 mg taken at bedtime or in two divided doses. Some patients may require and tolerate 1000 or 1200 mg per day. Common side effects include headache, dry mouth, constipation, weight gain, sedation, dizziness, and orthostatic hypotension.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risperidone
         </strong>
         –
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          Risperidone
         </a>
         is started at a dose of 1 to 2 mg once daily or in two divided doses. The usual target dose is 4 to 8 mg per day. It is usually taken in two divided doses per day, but some patients may do well with a single dose at bedtime. Common side effects include prolactin elevation, akathisia, sedation, dyspepsia, nausea, and weight gain. An oral dissolvable formulation is available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ziprasidone
         </strong>
         –
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          Ziprasidone
         </a>
         is started at a dose of 40 mg two times per day. The usual target dose is 40 to 80 mg two times per day. Some patients may require and tolerate larger doses; although doses of 320 mg/day have been studied, we suggest a maximum dose of 240 mg/day. Common side effects include headache, sedation, extrapyramidal symptoms, akathisia, and dizziness.
        </p>
        <p>
        </p>
        <p>
         Additional information about second-generation antipsychotics is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28431894">
         <span class="h1">
          TREATING SPECIFIC SUBGROUPS
         </span>
        </p>
        <p class="headingAnchor" id="H3686303614">
         <span class="h2">
          Rapid cycling patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pharmacotherapy for mania and hypomania that occur in the context of rapid cycling is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16847.html" rel="external">
          "Rapid cycling bipolar disorder in adults: Treatment of mania and hypomania"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1507783602">
         <span class="h2">
          Pregnant patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pharmacotherapy for antenatal mania and hypomania is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14647.html" rel="external">
          "Bipolar disorder in pregnant women: Screening, diagnosis, and choosing treatment for mania and hypomania"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1374120375">
         <span class="h2">
          Postpartum patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pharmacotherapy for postnatal mania and hypomania is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/83170.html" rel="external">
          "Bipolar disorder in postpartum women: Treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4180824697">
         <span class="h2">
          Geriatric patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pharmacotherapy for late-life mania and hypomania is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16446.html" rel="external">
          "Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Mania and hypomania'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1379206629">
         <span class="h2">
          Pediatric patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pharmacotherapy for pediatric mania and hypomania is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15925.html" rel="external">
          "Pediatric bipolar disorder: Overview of choosing treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3847223">
         <span class="h1">
          INDICATIONS FOR REFERRAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although some primary care clinicians have the requisite training and experience to manage bipolar disorder, many patients are referred to psychiatrists and other mental health clinicians if these specialists are available. Common indications for referral include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suicidal ideation and behavior
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psychotic features (eg, auditory hallucinations commanding patients to kill themselves)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fluctuating symptoms
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Impulsive and dangerous behavior
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Functional impairment
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Comorbid psychopathology (eg, anxiety disorders and substance use disorders)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multiple (eg, two to four) failed medication trials
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administration of adjunctive psychotherapy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrence of mood episodes
        </p>
        <p>
        </p>
        <p>
         Primary care clinicians who refer patients to specialists are encouraged to remain involved in management. General internists and other clinicians can help educate patients and families about pharmacotherapy and reinforce the need for adherence, and typically collaborate in evaluating patients prior to treatment and monitoring vital signs, weight, height, and waist size during treatment.
        </p>
        <p class="headingAnchor" id="H2028053853">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115361.html" rel="external">
          "Society guideline links: Bipolar disorder"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22958399">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15348.html" rel="external">
          "Patient education: Bipolar disorder (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16338.html" rel="external">
          "Patient education: Coping with high drug prices (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/4869.html" rel="external">
          "Patient education: Bipolar disorder (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/16279.html" rel="external">
          "Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Additional information for patients is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/119372.html" rel="external">
          "Acute bipolar mania and hypomania in adults: General principles of pharmacotherapy", section on 'Information for patients'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition of bipolar disorder
         </strong>
         – Bipolar disorder is characterized by episodes of mania  (
         <a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">
          table 1
         </a>
         ), hypomania  (
         <a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">
          table 2
         </a>
         ), and major depression  (
         <a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Definition of bipolar disorder'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General treatment principles
         </strong>
         – The general principles and issues that are involved in treating acute bipolar mania and hypomania include the nature of the evidence, similar approach for mania and hypomania, assessment and monitoring, level of care, goals, drug classes, duration of an adequate trial, predictors of response, relapse during maintenance treatment, destabilizing drugs, and indications for referral. (See
         <a class="medical medical_review" href="/z/d/html/119372.html" rel="external">
          "Acute bipolar mania and hypomania in adults: General principles of pharmacotherapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe manic episodes
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial treatment
         </strong>
         – For patients with severe mania, we suggest initial treatment with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         or
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         plus an antipsychotic, rather than monotherapy with lithium, valproate, or an antipsychotic  (
         <a class="graphic graphic_algorithm graphicRef119471" href="/z/d/graphic/119471.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). We generally combine lithium or valproate with
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         . (See
         <a class="local">
          'Initial treatment'
         </a>
         above and
         <a class="local">
          'Medication doses and side effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Treatment-resistant patients
         </strong>
         – For patients with severe, treatment-resistant mania that does not respond to one medication combination (
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         or
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         plus an antipsychotic), we suggest additional medication combination trials rather than electroconvulsive therapy (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Lithium is switched to valproate (or vice versa), and the antipsychotic is switched to another antipsychotic. (See
         <a class="local">
          'Treatment-resistant patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Treatment-refractory patients
         </strong>
         – For treatment-refractory patients with severe mania who do not respond to four to six medication combinations, we suggest electroconvulsive therapy rather than additional trials of pharmacotherapy combinations (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Treatment-refractory patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypomania or mild to moderate mania
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial treatment
         </strong>
         – For patients with acute hypomania or mild to moderate mania, we suggest initial treatment with
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         or
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         monotherapy rather than other drugs (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). However, reasonable alternatives include
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="8630" href="/z/d/drug information/8630.html" rel="external">
          asenapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="104184" href="/z/d/drug information/104184.html" rel="external">
          cariprazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ,
         <a class="drug drug_general" data-topicid="10174" href="/z/d/drug information/10174.html" rel="external">
          paliperidone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         , or
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         . In addition to efficacy and tolerability, the choice depends upon past response to medications, comorbid medical illness, concurrent medications, specific symptoms, and cost. (See
         <a class="local">
          'First-line monotherapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Treatment resistance
         </strong>
         – For patients with hypomania or mild to moderate mania that does not respond to three to five monotherapy drug trials, we suggest combining either
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         or
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         with an antipsychotic (other than
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         ) rather than additional monotherapy trials (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Another option is using lithium plus valproate. (See
         <a class="local">
          'Initial treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treating specific subgroups
         </strong>
         – Choosing pharmacotherapy for treating acute mania and hypomania in specific subgroups is discussed elsewhere:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16847.html" rel="external">
          "Rapid cycling bipolar disorder in adults: Treatment of mania and hypomania"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14647.html" rel="external">
          "Bipolar disorder in pregnant women: Screening, diagnosis, and choosing treatment for mania and hypomania"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/83170.html" rel="external">
          "Bipolar disorder in postpartum women: Treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16446.html" rel="external">
          "Geriatric bipolar disorder: Treatment of mania and major depression", section on 'Mania and hypomania'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15925.html" rel="external">
          "Pediatric bipolar disorder: Overview of choosing treatment"
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009; 10:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benazzi F. Bipolar II disorder : epidemiology, diagnosis and management. CNS Drugs 2007; 21:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIntyre RS, Yoon J. Efficacy of antimanic treatments in mixed states. Bipolar Disord 2012; 14 Suppl 2:22.
          </a>
         </li>
         <li class="breakAll">
          NICE National Institute for Health and Care Excellence. Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care. September 2014. http://www.nice.org.uk/guidance/CG185 (Accessed on November 18, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016; 30:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fountoulakis KN, Grunze H, Vieta E, et al. The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines. Int J Neuropsychopharmacol 2017; 20:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015; 49:1087.
          </a>
         </li>
         <li class="breakAll">
          Keck Jr. PE, McElroy SL. Treatment of bipolar disorder. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.1177.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhi GS, Gessler D, Outhred T. The use of lithium for the treatment of bipolar disorder: Recommendations from clinical practice guidelines. J Affect Disord 2017; 217:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ostacher MJ, Tandon R, Suppes T. Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Bipolar Disorder: A Novel, Practical, Patient-Centered Guide for Clinicians. J Clin Psychiatry 2016; 77:920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007; 64:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith LA, Cornelius V, Warnock A, et al. Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy. Acta Psychiatr Scand 2007; 115:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006; 67:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogawa Y, Tajika A, Takeshima N, et al. Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination/augmentation therapy versus monotherapy. CNS Drugs 2014; 28:989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tohen M, Bowden CL, Smulevich AB, et al. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry 2008; 192:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yatham LN, Grossman F, Augustyns I, et al. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 2003; 182:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sachs GS, Vanderburg DG, Karayal ON, et al. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2012; 73:1412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hilty DM, Brady KT, Hales RE. A review of bipolar disorder among adults. Psychiatr Serv 1999; 50:201.
          </a>
         </li>
         <li class="breakAll">
          Sachs, G. Approach to the patient with elevated, expansive, or irritable mood. In: The MGH Guide to Psychiatry in Primary Care, Stern, TA, Herman, JB, Slavin, PL (Eds), McGraw-Hill, New York 1998. p.347.
         </li>
         <li class="breakAll">
          American Psychiatric Association Task Force on Electroconvulsive Therapy. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging, American Psychiatric Association, 2001.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li XB, Tang YL, Wang CY, de Leon J. Clozapine for treatment-resistant bipolar disorder: a systematic review. Bipolar Disord 2015; 17:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirota T, Kishi T. Adenosine hypothesis in schizophrenia and bipolar disorder: a systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators. Schizophr Res 2013; 149:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen AT, Malmstrom T, Nasrallah HA. Allopurinol augmentation in acute mania: A meta-analysis of placebo-controlled trials. J Affect Disord 2018; 226:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartoli F, Crocamo C, Clerici M, Carrà G. Allopurinol as add-on treatment for mania symptoms in bipolar disorder: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2017; 210:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kulkarni J, Garland KA, Scaffidi A, et al. A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology 2006; 31:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zarate CA Jr, Singh JB, Carlson PJ, et al. Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord 2007; 9:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amrollahi Z, Rezaei F, Salehi B, et al. Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J Affect Disord 2011; 129:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yildiz A, Guleryuz S, Ankerst DP, et al. Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry 2008; 65:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henriksen TE, Skrede S, Fasmer OB, et al. Blue-blocking glasses as additive treatment for mania: a randomized placebo-controlled trial. Bipolar Disord 2016; 18:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011; 378:1306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yildiz A, Nikodem M, Vieta E, et al. A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med 2015; 45:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dauphinais D, Knable M, Rosenthal J, et al. Zonisamide for bipolar disorder, mania or mixed states: a randomized, double blind, placebo-controlled adjunctive trial. Psychopharmacol Bull 2011; 44:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pigott K, Galizia I, Vasudev K, et al. Topiramate for acute affective episodes in bipolar disorder in adults. Cochrane Database Syst Rev 2016; 9:CD003384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young AH, Geddes JR, Macritchie K, et al. Tiagabine in the treatment of acute affective episodes in bipolar disorder: efficacy and acceptability. Cochrane Database Syst Rev 2006; :CD004694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vasudev A, Macritchie K, Vasudev K, et al. Oxcarbazepine for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev 2011; :CD004857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner KD, Kowatch RA, Emslie GJ, et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2006; 163:1179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cipriani A, Saunders K, Attenburrow MJ, et al. A systematic review of calcium channel antagonists in bipolar disorder and some considerations for their future development. Mol Psychiatry 2016; 21:1324.
          </a>
         </li>
         <li class="breakAll">
          Shahrokh N, Hales RE, Phillips KA, Yudofsky SC. The Language of Mental Health: A Glossary of Psychiatric Terms, American Psychiatric Publishing, Inc., Washington, DC 2011. p.8.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garriga M, Pacchiarotti I, Kasper S, et al. Assessment and management of agitation in psychiatry: Expert consensus. World J Biol Psychiatry 2016; 17:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calver L, Drinkwater V, Gupta R, et al. Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomised controlled trial. Br J Psychiatry 2015; 206:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 2007; 68:1876.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2021; 55:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Preskorn SH, Zeller S, Citrome L, et al. Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial. JAMA 2022; 327:727.
          </a>
         </li>
         <li class="breakAll">
          HIGHLIGHTS OF PRESCRIBING INFORMATION. IGALMI (dexmedetomidine) sublingual film, for sublingual or buccal. Revised 4/2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215390s000lbl.pdf (Accessed on May 11, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kendall T, Morriss R, Mayo-Wilson E, et al. Assessment and management of bipolar disorder: summary of updated NICE guidance. BMJ 2014; 349:g5673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith LA, Cornelius V, Warnock A, et al. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 2007; 9:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cipriani A, Rendell JM, Geddes JR. Haloperidol alone or in combination for acute mania. Cochrane Database Syst Rev 2006; :CD004362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BALANCE investigators and collaborators, Geddes JR, Goodwin GM, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith LA, Cornelius V, Warnock A, et al. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 2007; 9:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013; 346:f3646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keck PE Jr, McElroy SL, Strakowski SM, Soutullo CA. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry 2000; 61 Suppl 4:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keck PE Jr, McElroy SL, Strakowski SM. Schizoaffective disorder: role of atypical antipsychotics. Schizophr Res 1999; 35 Suppl:S5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tohen M, McIntyre RS, Kanba S, et al. Efficacy of olanzapine in the treatment of bipolar mania with mixed features defined by DSM-5. J Affect Disord 2014; 168:136.
          </a>
         </li>
         <li class="breakAll">
          National Institute for Health and Care Excellence (NICE). Antenatal and postnatal mental health: clinical management and service guidance. NICE clinical guideline 192. December 2014. http://www.nice.org.uk/guidance/cg192 (Accessed on May 16, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maina G, Albert U, Salvi V, et al. Valproate or olanzapine add-on to lithium: an 8-week, randomized, open-label study in Italian patients with a manic relapse. J Affect Disord 2007; 99:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reischies FM, Hartikainen J, Berghöfer A. Initial lithium and valproate combination therapy in acute mania. Neuropsychobiology 2002; 46 Suppl 1:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griswold KS, Pessar LF. Management of bipolar disorder. Am Fam Physician 2000; 62:1343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curtin F, Schulz P. Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis. J Affect Disord 2004; 78:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradwejn J, Shriqui C, Koszycki D, Meterissian G. Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. J Clin Psychopharmacol 1990; 10:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glick ID, Suppes T, DeBattista C, et al. Psychopharmacologic treatment strategies for depression, bipolar disorder, and schizophrenia. Ann Intern Med 2001; 134:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drugs for psychiatric disorders. Treat Guidel Med Lett 2006; 4:35.
          </a>
         </li>
         <li class="breakAll">
          Labbate, LA, Fava, et al. Drugs for treatment of bipolar disorders. In: Handbook of Psychiatric Drug Therapy, 6th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2010. p.110.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman MP, Freeman SA. Lithium: clinical considerations in internal medicine. Am J Med 2006; 119:478.
          </a>
         </li>
         <li class="breakAll">
          Freeman, MP, Wiegand, et al. Lithium. In: The American Psychiatric Publishing Textbook of Psychopharmacology, 4th, Schatzberg, AF, Nemeroff, CB (Eds), American Psychiatric Publishing, Inc, Washington, D.C. 2009. p.697.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002; 68:167.
          </a>
         </li>
         <li class="breakAll">
          Information for healthcare professionals: suicidal behavior and ideation and antiepileptics drugs. Published January 31, 2008. Updated December 16, 2008. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm100192.htm (Accessed on December 10, 2009).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patorno E, Bohn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010; 303:1401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pugh MJ, Hesdorffer D, Wang CP, et al. Temporal trends in new exposure to antiepileptic drug monotherapy and suicide-related behavior. Neurology 2013; 81:1900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibbons RD, Hur K, Brown CH, Mann JJ. Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. Arch Gen Psychiatry 2009; 66:1354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leon AC, Solomon DA, Li C, et al. Antiepileptic drugs for bipolar disorder and the risk of suicidal behavior: a 30-year observational study. Am J Psychiatry 2012; 169:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med 2010; 363:542.
          </a>
         </li>
         <li class="breakAll">
          Wang PW, Ketter TA, Post RM. Carbamazepine, oxcarbazepine, and licarbazepine. In: The American Psychiatric Association Publishing Textbook of Psychopharmacology, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.941.
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Mallakh RS, Salem MR, Chopra AS, et al. Adverse event load in bipolar participants receiving either carbamazepine immediate-release or extended-release capsules: a blinded, randomized study. Int Clin Psychopharmacol 2009; 24:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sachs GS, Thase ME. Bipolar disorder therapeutics: maintenance treatment. Biol Psychiatry 2000; 48:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keck PE Jr, McElroy SL, Strakowski SM. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 1998; 59 Suppl 6:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999; 353:2190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Man CB, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48:1015.
          </a>
         </li>
         <li class="breakAll">
          Bowden, CL. Valproate. In: The American Psychiatric Publishing Textbook of Psychopharmacology, 4th, Schatzberg, AF, Nemeroff, CB (Eds), American Psychiatric Publishing, Inc., Washington, D.C. 2009. p.719.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keck PE Jr, McElroy SL, Tugrul KC, Bennett JA. Valproate oral loading in the treatment of acute mania. J Clin Psychiatry 1993; 54:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fountoulakis KN, Yatham L, Grunze H, et al. The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm. Int J Neuropsychopharmacol 2017; 20:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowden CL, Mosolov S, Hranov L, et al. Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. Int Clin Psychopharmacol 2010; 25:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirschfeld RM, Allen MH, McEvoy JP, et al. Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. J Clin Psychiatry 1999; 60:815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reed RC, Dutta S. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER? Ther Drug Monit 2006; 28:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen MH, Hirschfeld RM, Wozniak PJ, et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 2006; 163:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haymond J, Ensom MH. Does valproic acid warrant therapeutic drug monitoring in bipolar affective disorder? Ther Drug Monit 2010; 32:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prien RF, Caffey EM Jr, Klett CJ. Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group. Arch Gen Psychiatry 1972; 26:146.
          </a>
         </li>
         <li class="breakAll">
          Medical treatment of hypomania, mania, and mixed states. In: Manic-Depressive Illness:Bipolar Disorders and Recurrent Depression, 2nd, Goodwin, FK, Jamison, KR (Eds), Oxford University Press, Oxford 2007. p.736.
         </li>
         <li>
          <a class="nounderline abstract_t">
           McElroy SL, Keck PE, Stanton SP, et al. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996; 57:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goikolea JM, Colom F, Torres I, et al. Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. J Affect Disord 2013; 144:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIntyre RS, Cohen M, Zhao J, et al. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord 2010; 122:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIntyre RS, Cohen M, Zhao J, et al. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009; 11:673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vieta E, Nuamah IF, Lim P, et al. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord 2010; 12:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berwaerts J, Xu H, Nuamah I, et al. Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study. J Affect Disord 2012; 136:e51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berwaerts J, Lane R, Nuamah IF, et al. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. J Affect Disord 2011; 129:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Earley W, Durgam S, Lu K, et al. Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies. J Affect Disord 2017; 215:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nemeroff CB, Lieberman JA, Weiden PJ, et al. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr 2005; 10:1.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 679 Version 79.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19347775" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17696573" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Bipolar II disorder : epidemiology, diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22510034" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Efficacy of antimanic treatments in mixed states.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22510034" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Efficacy of antimanic treatments in mixed states.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29536616" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26979387" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27941079" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26643054" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26643054" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28437764" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The use of lithium for the treatment of bipolar disorder: Recommendations from clinical practice guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26580001" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Bipolar Disorder: A Novel, Practical, Patient-Centered Guide for Clinicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17404121" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17201861" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16669715" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25160685" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination/augmentation therapy versus monotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18245032" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12562742" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23218157" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10030478" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A review of bipolar disorder among adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10030478" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A review of bipolar disorder among adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10030478" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A review of bipolar disorder among adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25346322" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Clozapine for treatment-resistant bipolar disorder: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23870805" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Adenosine hypothesis in schizophrenia and bipolar disorder: a systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29017068" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Allopurinol augmentation in acute mania: A meta-analysis of placebo-controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27856422" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Allopurinol as add-on treatment for mania symptoms in bipolar disorder: systematic review and meta-analysis of randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16356651" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17845270" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20843556" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18316672" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27226262" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Blue-blocking glasses as additive treatment for mania: a randomized placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11106131" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21851976" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25036226" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22506436" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Zonisamide for bipolar disorder, mania or mixed states: a randomized, double blind, placebo-controlled adjunctive trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27591453" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Topiramate for acute affective episodes in bipolar disorder in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16856056" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Tiagabine in the treatment of acute affective episodes in bipolar disorder: efficacy and acceptability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22161387" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Oxcarbazepine for acute affective episodes in bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16816222" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27240535" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : A systematic review of calcium channel antagonists in bipolar disorder and some considerations for their future development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27240535" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A systematic review of calcium channel antagonists in bipolar disorder and some considerations for their future development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26912127" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Assessment and management of agitation in psychiatry: Expert consensus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25395689" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental health: randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18162018" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33353391" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35191924" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35191924" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25258392" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Assessment and management of bipolar disorder: summary of updated NICE guidance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17845269" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16856043" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Haloperidol alone or in combination for acute mania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20092882" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17547586" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23814104" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10739329" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10190221" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Schizoaffective disorder: role of atypical antipsychotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25046739" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Efficacy of olanzapine in the treatment of bipolar mania with mixed features defined by DSM-5.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25046739" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Efficacy of olanzapine in the treatment of bipolar mania with mixed features defined by DSM-5.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17056122" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Valproate or olanzapine add-on to lithium: an 8-week, randomized, open-label study in Italian patients with a manic relapse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12571429" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Initial lithium and valproate combination therapy in acute mania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11011863" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Management of bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15013244" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2126794" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Double-blind comparison of the effects of clonazepam and lorazepam in acute mania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11187420" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Psychopharmacologic treatment strategies for depression, bipolar disorder, and schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16770298" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Drugs for psychiatric disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16770298" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Drugs for psychiatric disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16750958" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Lithium: clinical considerations in internal medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16750958" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Lithium: clinical considerations in internal medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12063145" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Mortality of patients with mood disorders: follow-up over 34-38 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12063145" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Mortality of patients with mood disorders: follow-up over 34-38 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20388896" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24174583" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Temporal trends in new exposure to antiepileptic drug monotherapy and suicide-related behavior.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19996040" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22193537" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Antiepileptic drugs for bipolar disorder and the risk of suicidal behavior: a 30-year observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20818889" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Suicide-related events in patients treated with antiepileptic drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20818889" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Suicide-related events in patients treated with antiepileptic drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19367153" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Adverse event load in bipolar participants receiving either carbamazepine immediate-release or extended-release capsules: a blinded, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11018228" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Bipolar disorder therapeutics: maintenance treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9674940" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Anticonvulsants and antipsychotics in the treatment of bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10392983" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15057820" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Medical genetics: a marker for Stevens-Johnson syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16538176" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17509004" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17509004" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8253698" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Valproate oral loading in the treatment of acute mania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27816941" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20101186" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10665626" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16778728" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16449481" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19901867" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Does valproic acid warrant therapeutic drug monitoring in bipolar affective disorder?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4551257" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4551257" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Comparison of lithium carbonate and chlorpromazine in the treatment of mania. Report of the Veterans Administration and National Institute of Mental Health Collaborative Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8601548" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23089129" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20096936" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19839993" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20565430" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20624657" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20947174" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28343051" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16381088" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : From clinical research to clinical practice: a 4-year review of ziprasidone.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
